Method for treating negative symptoms of schizophrenia

WO2026136179A1PCT designated stage Publication Date: 2026-06-25REVIVA PHARMACEUTICALS INC

Patent Information

Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner: REVIVA PHARMACEUTICALS INC
Filing Date: 2025-12-12
Publication Date: 2026-06-25

AI Technical Summary

Technical Problem

Current pharmacological therapies are ineffective in treating the negative symptoms of schizophrenia, which are a core component of the disorder and contribute significantly to long-term disability, despite the need for targeted treatments endorsed by regulatory agencies.

Method used

Administering brilaroxazine, a multimodal dopamine and serotonin receptor modulator, to patients with negative symptoms, utilizing various rating instruments to select and measure severity, and formulating it into suitable pharmaceutical compositions for systemic or local administration.

Benefits of technology

Brilaroxazine demonstrates significant and durable reduction in negative symptoms, as evidenced by PANSS and Marder factor scale reductions, with improved speech latency as an objective biomarker, showing efficacy over 12 months.

✦ Generated by Eureka AI based on patent content.

Smart Images

Figure US2025059527_25062026_PF_FP_ABST

Patent Text Reader

Abstract

The present invention provides a method of using brilaroxazine or a pharmaceutically acceptable salt for treating mild to severe negative symptoms of schizophrenia. The method comprises selecting a patient having moderate to severe negative symptoms of schizophrenia, and administering to the patient an effective amount of brilaroxazine or a pharmaceutically acceptable salt. A preferred route of administration is oral administration.

Need to check novelty before this filing date? Find Prior Art